Vlad Coric, Biohaven CEO
Biohaven’s autoimmune drug disappoints investors in study of healthy volunteers
In a closely watched readout, Biohaven’s autoimmune disease treatment led to a 37% reduction on average in levels of harmful antibodies at the highest reported …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
